#### Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3

#### DUSA PHARMACEUTICALS INC

Form 3

November 27, 2007

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF

**SECURITIES** 

30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| 1. Name and Address of Reporting Person *  Flynn James E   |          |          | 2. Date of Event Requiring Statement (Month/Day/Year) |   | 3. Issuer Name and Ticker or Trading Symbol DUSA PHARMACEUTICALS INC [DUSA] |  |                         |   |  |
|--|----------|----------|---|---|---|--|-------------------------|---|--|
| , ,  | (First)  | (Middle) | 10/30/2007  | •   | 4. Relationship of Reporting Person(s) to Issuer                            |  | g                       | 5. If Amendment, Date Original Filed(Month/Day/Year)        |  |
| 780 THIRD AVENUE, 37TH<br>FLOOR  |          |          |   |   | (Check  | all applicable   |                         |   |  |
|  | (Street) |          |   |   | DirectorX10% Ov<br>Officer Other<br>(give title below) (specify below)      |  |                         | Filing(Check Applicable Line)  Form filed by One Reporting  |  |
| NEW YORK, NY 10017   |          |          |   |   |   |  |                         | Person _X_ Form filed by More than One Reporting Person     |  |
| (City)   | (State)  | (Zip)    |   | Table I - N                               | Non-Derivat   | tive Securit   | ies Be                  | neficially Owned  |  |
| 1.Title of Security (Instr. 4)   | y        |          |   | 2. Amount o<br>Beneficially<br>(Instr. 4) |   | 3.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) | 4. Na<br>Owne<br>(Instr | •   |  |
| Common Stoc  | k (1)    |          |   | 837,956                                   |   | I (2)  |                         | ough Deerfield Special ations Fund, L.P.                    |  |
| Common Stoc  | k (1)    |          |   | 1,535,857                                 |   | I (3)  |                         | ough Deerfield Special<br>ations Fund International<br>sted |  |
| Reminder: Report on a separate line for each class of securities be owned directly or indirectly.  |          |          | urities benefic                                       | <sup>ially</sup> S                        | EC 1473 (7-0  | 2)   |                         |   |  |
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |          |          |   |   |   |  |                         |   |  |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

### Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exerci<br>Expiration Dat<br>(Month/Day/Year) |                    | 3. Title and Amount of<br>Securities Underlying<br>Derivative Security<br>(Instr. 4) |                                  | 4.<br>Conversion<br>or Exercise<br>Price of | 5.<br>Ownership<br>Form of<br>Derivative        | 6. Nature of Indirect<br>Beneficial<br>Ownership<br>(Instr. 5) |  |
|--|--|--------------------|--|----------------------------------|---|---|--|--|
|  | Date<br>Exercisable                                  | Expiration<br>Date | Title  | Amount or<br>Number of<br>Shares | Derivative<br>Security                      | Security: Direct (D) or Indirect (I) (Instr. 5) |  |  |
| Warrants                                   | 10/30/2007   | 04/30/2013         | Common<br>Stock  | 209,489                          | \$ 2.85                                     | I   | See Note (2)   |  |
| Warrants                                   | 10/30/2007   | 04/30/2013         | Common<br>Stock  | 383,964                          | \$ 2.85                                     | I   | See Note (3)   |  |

# **Reporting Owners**

| Reporting Owner Name / Address   | Relationships |           |         |       |  |  |
|--|---------------|-----------|---------|-------|--|--|
| <b>Fg</b>  | Director      | 10% Owner | Officer | Other |  |  |
| Flynn James E<br>780 THIRD AVENUE<br>37TH FLOOR<br>NEW YORK, NY 10017  | Â             | ÂΧ        | Â       | Â     |  |  |
| DEERFIELD CAPITAL LP<br>780 THIRD AVENUE<br>37TH FLOOR<br>NEW YORK, NY 10017   | Â             | ÂX        | Â       | Â     |  |  |
| Deerfield Special Situations Fund, L.P.<br>780 3RD AVENUE<br>37TH FLOOR<br>NEW YORK, NY 10017  | Â             | ÂX        | Â       | Â     |  |  |
| DEERFIELD MANAGEMENT CO /NY<br>780 THIRD AVENUE, 37TH FLOOR<br>NEW YORK, NY 10017  | Â             | ÂX        | Â       | Â     |  |  |
| Deerfield Special Situations Fund International LTD C/O HEMISPHERE MANAGEMENT (B.V.I.) COLUMBUS CENTRE, P.O. BOX 3460 ROAD TOWN, TORTOLA, D8 - | Â             | ÂX        | Â       | Â     |  |  |

## **Signatures**

/s/ Darren
Levine

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

### Edgar Filing: DUSA PHARMACEUTICALS INC - Form 3

- (1) This Form 3 is being filed by the undersigned s well as the entities listed on the Joint Filer Information Statement attached as an exhibit hereto (the "Reporting Persons").
  - Deerfield Capital, L.P. is the general partner of Deerfield Special Situations Fund, L.P. (the "Domestic Fund"). James E. Flynn is the managing member of the general partner of Deerfield Capital, L.P. In accordance with Instruction 5 (b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Domestic Fund is reported begin. For purposes of Section 16 of the Securities Exchange Act of
- of the Issuer's securities held by the Domestic Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
- Deerfield Management Company, L.P. is the investment manager of Deerfield Special Situations Fund International Limited (the "Offshore Fund"). James E. Flynn is the managing member of the general partner of Deerfield Management Company, L.P. In accordance with Instruction 5(b)(iv) to Form 3, the entire amount of the Issuer's securities held by the Offshore Fund is reported herein. For purposes of Section 16 of the Securities Exchange Act of 1934, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its indirect pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.



#### **Remarks:**

Darren Levine, Attorney-In-Fact: Power of Attorney is attached hereto as Exhibit 24

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.